Page 1 of 6 Recommendations for the production of Anti-Covid Natural Compounds Chlorogenic acid (C16H18O9) (CGA) - ester of coffee (3,4-dioxycinnamic) acid and one of the stereoisomers of quinic acid, widely distributed in nature and is found in the greatest amount in coffee beans, sunflower seeds, leaves blueberry and white poplar, chicory root. Biosynthesis of CGA occurs exclusively in plants from phenylalanine through the stage of shikimic acid formation. CGA has strong antioxidant properties, antiviral, antibacterial and antifungal properties, exhibits hypoglycemic, hypocholesterolemic, anticancer and hepatoprotective effects. Its prebiotic properties. Despite the "chloro" of the name, chlorogenic acids contain no chlorine. Instead, the name comes from the Greek χλωρός (light green) and -γένος (a suffix meaning "giving rise to"), pertaining to the green color produced when chlorogenic acids are oxidized. Chlorogenic acid - Candidate molecule for antiviral drug against COVID 19 Introduction Human experience from the field of chemotherapy for viral infections shows that a specific antiviral drug used in medical practice, taking into account international recognition, certainly must meet three fundamental requirements: The first is that the antiviral drug should act only at a certain stage of the reproduction of the virus, this effect should be strictly selective. Damage to one or another stage of virus reproduction should not affect the life of the cells, organs, and the host organism. Antiviral drugs theoretically should not have side effects, for example, the primary damage to the synthesis of viral nucleic acids should be strictly selective and not be accompanied by inhibition of the synthesis of the actual cellular nucleic acids. The safety and tolerability of drugs is determined by this property of an antiviral substance. The second is an anti-virus compound (i.e. drugs) with such unique properties that should have optimal bioavailability, pharmacokinetic properties during its use for medical purposes. Its concentration in the blood, in cellular systems and organs affected by a viral infection, should significantly exceed that concentration of the drug that provides a pronounced antiviral effect in vitro experiments, and such a concentration should be maintained constantly in the patient's body during the entire course of the use of antiviral drugs. The optimal concentration of the antiviral drug is crucial to prevent the development of drug resistance due to the formation of a mutant viral population resistant to the study drug. Therefore, it is important in the process of both preclinical and clinical studies of the antiviral drug to form the optimal scheme for its use.